News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 31, 2016

Clinical Trials for Cancer Treatment

Episodes in this series

EP. 1 Freda's Story: Her Diagnosis of CRC

EP. 1 Freda's Story: Her Diagnosis of CRC

EP. 2 Interventional Radiologist's Role

EP. 2 Interventional Radiologist's Role

EP. 3 Considering a Second Opinion for Cancer Care

EP. 3 Considering a Second Opinion for Cancer Care

EP. 4 It Takes a Team to Treat Cancer

EP. 4 It Takes a Team to Treat Cancer

EP. 5 Treatment of Metastatic Colorectal Cancer

EP. 5 Treatment of Metastatic Colorectal Cancer

EP. 6 Clinical Trials for Cancer Treatment

EP. 6 Clinical Trials for Cancer Treatment

EP. 7 Improving Care For Patients

EP. 7 Improving Care For Patients

EP. 8 Freda: Managing Aggressive Treatment

EP. 8 Freda: Managing Aggressive Treatment

EP. 9 Finding the Right Treatment Option

EP. 9 Finding the Right Treatment Option

EP. 10 How to Pay for Treatment Options

EP. 10 How to Pay for Treatment Options

Newsletter

Stay up to date on cancer updates, research and education

Related Content

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer: © stock.adobe.com.

Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC

January 28th 2026

Dr. Anne Peled

Breast Cancer Surgeon and Survivor Undergoes Nerve-Sparing Procedure

January 27th 2026

Dr. Anne Peled

Two-Time Breast Cancer Survivor Shares Advice for Fellow Patients

ByDr. Anne Peled

January 27th 2026

Debbie Legault

Cancer and Answering the Phone

ByDebbie Legault

January 27th 2026

As patients with advanced cancer near the end of life, reducing unnecessary medications may help prioritize comfort, quality of life, and symptom relief: © stock.adobe.com

Rethinking Medications at the End of Life for Patients With Advanced Cancer

January 27th 2026

Trending on CURE

Cancer and Answering the Phone

Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC

Besremi Recognized by Updated Guidelines for Essential Thrombocythemia

FDA Grants Orphan Drug Status to CTD402 for Rare T-Cell Blood Cancers

Grieving After Cancer: Advice for Those Grieving and Supporting Them